Biological Agents Indicated for Rheumatoid Arthritis
The biological agents indicated for rheumatoid arthritis from your list are: a) Abatacept, c) Infliximab, and e) Certolizumab. Nivolumab is an immune checkpoint inhibitor for cancer, and bortezomib is a proteasome inhibitor for multiple myeloma—neither has any role in RA treatment.
Approved Biological DMARDs for RA
Based on current EULAR and international guidelines, the following agents from your list are specifically approved for RA treatment 1:
TNF Inhibitors
- Infliximab: A chimeric mouse/human anti-TNFα monoclonal antibody administered intravenously, approved since 2000 for RA treatment 1
- Certolizumab pegol: A PEGylated Fab' fragment of an anti-TNFα antibody lacking the Fc portion, administered subcutaneously 1
Both are listed among the five approved TNF inhibitors (along with adalimumab, etanercept, and golimumab) in the 2019 Autoimmunity Reviews guidelines 1.
Non-TNF Biological Agent
- Abatacept: A recombinant fusion protein that selectively modulates T-cell co-stimulation, approved in the EU for highly active and progressive RA in both methotrexate-naive patients and those with inadequate response to conventional DMARDs or TNF inhibitors 1
The 2014 EULAR recommendations explicitly list these agents, stating that when csDMARDs fail in patients with poor prognostic factors, "TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab), abatacept, rituximab, or tocilizumab should be added" 2.
Agents NOT Indicated for RA
Nivolumab (Option b)
Nivolumab is a PD-1 immune checkpoint inhibitor approved exclusively for various cancers including gastric cancer, melanoma, and lung cancer 3. It has no indication whatsoever for rheumatoid arthritis and would be contraindicated given its mechanism of enhancing immune responses—the opposite of what RA requires.
Bortezomib (Option d)
Bortezomib is a proteasome inhibitor approved only for multiple myeloma and mantle cell lymphoma 4. It has no role in RA treatment and is not mentioned in any rheumatology guidelines or RA literature.
Clinical Context
All three RA-indicated biologics should preferentially be combined with methotrexate or other conventional synthetic DMARDs 2, 5. The 2020 EULAR recommendations specify that biologics should be added when the treatment target is not achieved with first-line csDMARD strategy in patients with poor prognostic factors (high disease activity, positive RF/ACPA, early erosions) 5.
The choice among these agents depends on:
- Prior treatment failures: Abatacept, infliximab, and certolizumab are all appropriate after methotrexate failure 1, 2
- TNF inhibitor failure: Abatacept remains effective after TNF inhibitor failure, while switching between TNF inhibitors (like trying certolizumab after infliximab failure) has less robust evidence 2
- Contraindications: Specific patient factors like history of tuberculosis, malignancy, or demyelinating disease may favor one agent over another 2
Recent head-to-head data from the NORD-STAR trial showed certolizumab achieved 52.3% CDAI remission at 48 weeks versus 39.2% with active conventional therapy, demonstrating superiority 6. Abatacept has shown consistent efficacy across multiple trials with low immunogenicity rates 7, 8.